BNC Korea (256840) Fundamentals 2026 — Revenue Analysis | SniperIQ
BNC Korea (256840) is a KR-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₩158.7B, trading at ₩2320.00 on the KOE. This SniperIQ fundamentals page covers BNC Korea's valuation, profitability (net margin -3.6%), revenue (₩95.9B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is BNC Korea's market cap?
BNC Korea (256840) has a market capitalization of approximately ₩158.7B, trading at ₩2320.00 on the KOE. Market cap moves with the live share price.
What is BNC Korea's P/E ratio?
BNC Korea's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is BNC Korea?
BNC Korea runs a net profit margin of -3.6%, a gross margin of 38.2%, and an operating margin of -3.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does BNC Korea generate?
BNC Korea reported revenue of ₩95.9B for fiscal year 2025, with net income of ₩2.8B and earnings per share (EPS) of 45.41. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does BNC Korea pay a dividend?
BNC Korea offers a trailing dividend yield of about 3.0%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is BNC Korea financially healthy?
BNC Korea carries a debt-to-equity ratio of 0.12x and a current ratio of 5.10x, with a market beta of 0.52. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is BNC Korea a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For BNC Korea (256840) the key facts are: market cap ₩158.7B, revenue ₩95.9B, 52-week range 2230-6180. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track BNC Korea's full fundamentals live
Get BNC Korea's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.